Maternal and infant immunity against <i>Bordetella pertussis,</i> Norway, 2020 to 2023.

ABSTRACT: BACKGROUNDPertussis remains a serious threat to young infants. In Norway, infants receive an acellular pertussis vaccine (aP) according to a 2 + 1 schedule at 3, 5 and 12 months of age, delivered as a hexavalent vaccine.AIMWe aimed to study susceptibility to pertussis in mothers and infants to guide decisions regarding vaccination in pregnancy.METHODSIn this prospective observational study, we included 366 mother/infant pairs during 2020-2023, collecting blood samples from mothers in late pregnancy, cord blood at delivery and from infants before their first and after their third vaccine dose. We retrieved health registry data on vaccination and pregnancy-related information. IgG antibody levels against pertussis-antigens, diphtheria and tetanus were measured using a multiplex immunoassay.R

SUBMITTER: Greve-Isdahl M 

PROVIDER: S-EPMC12719935 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature